PT3107914T - Compostos de pirazolo[1,5-a]pirimidina-5,7-diamina como inibidores de cdk e utilização terapêutica dos mesmos - Google Patents

Compostos de pirazolo[1,5-a]pirimidina-5,7-diamina como inibidores de cdk e utilização terapêutica dos mesmos

Info

Publication number
PT3107914T
PT3107914T PT15706282T PT15706282T PT3107914T PT 3107914 T PT3107914 T PT 3107914T PT 15706282 T PT15706282 T PT 15706282T PT 15706282 T PT15706282 T PT 15706282T PT 3107914 T PT3107914 T PT 3107914T
Authority
PT
Portugal
Prior art keywords
pyrazolo
pyrimidine
therapeutic use
diamine compounds
cdk inhibitors
Prior art date
Application number
PT15706282T
Other languages
English (en)
Portuguese (pt)
Inventor
Bondke Alexander
kroll Sebastian
Barrett Anthony
Fuchter Matthew
Slafer Brian
Ali Simak
Coombes Charles
Patrick Snyder James
Original Assignee
Univ Emory
Cancer Research Tech Ltd
Ip2Ipo Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Emory, Cancer Research Tech Ltd, Ip2Ipo Innovations Ltd filed Critical Univ Emory
Publication of PT3107914T publication Critical patent/PT3107914T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PT15706282T 2014-02-21 2015-02-20 Compostos de pirazolo[1,5-a]pirimidina-5,7-diamina como inibidores de cdk e utilização terapêutica dos mesmos PT3107914T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB201403093A GB201403093D0 (en) 2014-02-21 2014-02-21 Therapeutic compounds and their use

Publications (1)

Publication Number Publication Date
PT3107914T true PT3107914T (pt) 2019-05-20

Family

ID=50482596

Family Applications (1)

Application Number Title Priority Date Filing Date
PT15706282T PT3107914T (pt) 2014-02-21 2015-02-20 Compostos de pirazolo[1,5-a]pirimidina-5,7-diamina como inibidores de cdk e utilização terapêutica dos mesmos

Country Status (23)

Country Link
US (4) US9932344B2 (OSRAM)
EP (1) EP3107914B8 (OSRAM)
JP (1) JP6498212B2 (OSRAM)
CN (1) CN106103445B (OSRAM)
AU (1) AU2015220560B2 (OSRAM)
BR (1) BR112016018633B1 (OSRAM)
CA (1) CA2939786C (OSRAM)
CY (1) CY1121588T1 (OSRAM)
DK (1) DK3107914T3 (OSRAM)
ES (1) ES2721268T3 (OSRAM)
GB (1) GB201403093D0 (OSRAM)
HR (1) HRP20190685T1 (OSRAM)
HU (1) HUE043122T2 (OSRAM)
LT (1) LT3107914T (OSRAM)
ME (1) ME03427B (OSRAM)
NZ (1) NZ724323A (OSRAM)
PL (1) PL3107914T3 (OSRAM)
PT (1) PT3107914T (OSRAM)
RS (1) RS58704B1 (OSRAM)
SI (1) SI3107914T1 (OSRAM)
SM (1) SMT201900266T1 (OSRAM)
TR (1) TR201905647T4 (OSRAM)
WO (1) WO2015124941A1 (OSRAM)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201403093D0 (en) 2014-02-21 2014-04-09 Cancer Rec Tech Ltd Therapeutic compounds and their use
EP3214086B1 (en) 2014-10-31 2021-09-22 Ube Industries, Ltd. Substituted dihydropyrrolopyrazole compound
EP3233842B1 (en) 2014-12-17 2025-03-26 King's College London Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (rarb) agonists
EP3256475A4 (en) * 2015-02-13 2019-02-13 Dana-Farber Cancer Institute, Inc. LRRK2 INHIBITORS AND METHOD FOR THE PRODUCTION AND USE THEREOF
KR102588426B1 (ko) 2015-06-15 2023-10-13 유비이 가부시키가이샤 치환 디히드로피롤로피라졸 유도체
WO2017096326A1 (en) 2015-12-02 2017-06-08 Massachusetts Institute Of Technology Method for efficient generation of neurons from non-neuronal cells
CR20190157A (es) 2016-08-31 2019-08-13 Agios Pharmaceuticals Inc Inhibidores de procesos metabólicos celulares
DK3658557T3 (da) 2017-07-28 2024-07-29 Takeda Pharmaceuticals Co Tyk2-inhibitorer og anvendelser deraf
EP3666770A4 (en) * 2017-08-07 2021-04-07 Joint Stock Company "Biocad" NEW HETEROCYCLIC COMPOUNDS AS CDK8 / 19 INHIBITORS
US20200197392A1 (en) * 2017-08-15 2020-06-25 The Brigham & Women's Hospital, Inc. Compositions and methods for treating tuberous sclerosis complex
GB201715194D0 (en) * 2017-09-20 2017-11-01 Carrick Therapeutics Ltd Compounds and their therapeutic use
TWI703149B (zh) * 2017-11-16 2020-09-01 美商美國禮來大藥廠 用於抑制cdk7之化合物
CA3095880A1 (en) * 2018-04-11 2019-10-17 Qurient Co., Ltd. Pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives as selective inhibitor of cyclin dependent kinase
WO2019213403A1 (en) 2018-05-02 2019-11-07 Kinnate Biopharma Inc. Inhibitors of cyclin-dependent kinases
KR20210040368A (ko) 2018-06-29 2021-04-13 킨네이트 바이오파마 인크. 사이클린 의존성 키나제의 억제제
MD20210033A2 (ro) 2018-10-30 2021-10-31 Kronos Bio, Inc. Compuşi, compoziţii şi metode pentru modularea activităţii CDK9
US12304913B2 (en) 2018-11-14 2025-05-20 Ube Industries, Ltd. Dihydropyrrolopyrazole derivative
CN109860354B (zh) * 2018-12-28 2020-05-19 南京邮电大学 同质集成红外光子芯片及其制备方法
US20220144841A1 (en) * 2019-03-13 2022-05-12 The Translational Genomics Research Institute Trisubstituted pyrazolo [1,5-a] pyrimidine compounds as cdk7 inhibitors
JP2022539849A (ja) * 2019-07-10 2022-09-13 オーセントラ セラピュティクス ピーティーワイ エルティーディー 治療薬としての4-(イミダゾ[1,2-a]ピリジン-3-イル)-N-(ピリジニル)ピリミジン-2-アミンの誘導体
WO2021087138A1 (en) * 2019-10-29 2021-05-06 Syros Pharmaceuticals, Inc. Methods of treating cancer in biomarker-identified patients with inhibitors of cyclin-dependent kinase 7 (cdk7)
GB201918541D0 (en) 2019-12-16 2020-01-29 Carrick Therapeutics Ltd Therapeutic compounds and their use
CN115485030A (zh) * 2020-03-06 2022-12-16 拜耳公司 咪唑并三嗪通过抑制cdk12作用于癌症
WO2021216828A1 (en) * 2020-04-24 2021-10-28 Massachusetts Institute Of Technology Chimeric degraders of cyclin-dependent kinase 9 and uses thereof
CN116761609B (zh) * 2021-01-22 2025-08-26 上海海雁医药科技有限公司 取代的吡唑并[1,5-a]嘧啶-7-胺衍生物、其组合物及医药上的用途
CN117715904A (zh) 2021-05-07 2024-03-15 凯麦拉医疗公司 Cdk2降解剂和其用途
GB202108572D0 (en) * 2021-06-16 2021-07-28 Carrick Therapeutics Ltd Therapeutic compounds and their use
WO2023001061A1 (en) * 2021-07-17 2023-01-26 Jingrui Biopharma Co., Ltd. Cdk7 selective inhibitors as anticancer agents
AU2022398230A1 (en) * 2021-11-24 2024-06-13 Kronos Bio, Inc. Polymorphic and salt forms of (1s,3s)-n1-(5-(pentan-3- yl)pyrazolo[1,5-a]pyrimidin-7-yl)cyclopentane-1,3-diamine
WO2024102447A1 (en) * 2022-11-10 2024-05-16 Emory University Uses of hydroimidazopyridopyrimidinone derivatives for managing aneurysms or other vascular conditions or diseases
EP4671245A1 (en) * 2023-02-20 2025-12-31 Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. HETEROAROMATIC CYCLIC COMPOUND SERVING AS A CDK7 KINASE INHIBITOR, ITS PREPARATION AND USE
CN120712267A (zh) * 2023-02-21 2025-09-26 杭州德睿智药科技有限公司 作为CDKs抑制剂的新型并杂环类新化合物及其应用
WO2025006569A1 (en) 2023-06-27 2025-01-02 Arvinas Operations, Inc. Combinations of estrogen receptor degraders and cdk7 inhibitors for the treatment of cancer
WO2025057087A1 (en) 2023-09-11 2025-03-20 Assia Chemical Industries Ltd. Solid state forms of samuraciclib
WO2025208104A1 (en) * 2024-03-29 2025-10-02 The Translational Genomics Research Institute Cdk7 inhibitors and methods of use thereof
WO2025208097A1 (en) * 2024-03-29 2025-10-02 The Translational Genomics Research Institute Cdk7 inhibitors and methods of use thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003519143A (ja) 1999-12-28 2003-06-17 ファーマコピーア,インコーポレーティッド ピリミジン及びトリアジン系キナーゼ阻害剤
AU2003263071B2 (en) 2002-09-04 2007-03-15 Merck Sharp & Dohme Llc Pyrazolopyrimidines as cyclin-dependent kinase inhibitors
EP1592689A4 (en) 2003-01-31 2008-12-24 Merck & Co Inc 3-AMINO-4-PHENYLBUTANEAN DERIVATIVES AS DIPEPTIDYLPEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
BRPI0407834A (pt) 2003-02-28 2006-02-14 Teijin Pharma Ltd composto, processo para a manufatura do mesmo, composição, processo para a manufatura da mesma, método de tratamento ou prevenção de um distúrbio mediado por proteìna quinase em um indivìduo, uso de um composto, ensaio para determinar a atividade dos compostos, e, método de inibição da atividade ou função de uma proteìna quinase
WO2004087707A1 (en) * 2003-03-31 2004-10-14 Vernalis (Cambridge) Limited Pyrazolopyrimidine compounds and their use in medicine
JO2478B1 (en) 2003-06-19 2009-01-20 جانسين فارماسوتيكا ان. في. (Aminomethyl) -biperidine benzamides as 5 HT4 antagonists
WO2007044441A2 (en) * 2005-10-06 2007-04-19 Schering Corporation Use of pyrazolo [1 , 5 -a] pyrimidine derivatives for inhibiting protein kinases methods for inhibiting protein kinases
AU2008261027A1 (en) * 2007-06-05 2008-12-11 Emory University Selective inhibitors for cyclin-dependent kinases
AU2010326268B2 (en) * 2009-12-04 2016-11-03 Senhwa Biosciences, Inc. Pyrazolopyrimidines and related heterocycles as CK2 inhibitors
WO2012059932A1 (en) 2010-11-01 2012-05-10 Aurigene Discovery Technologies Limited 2, 4 -diaminopyrimidine derivatives as protein kinase inhibitors
JP6105578B2 (ja) * 2011-07-21 2017-03-29 トレロ ファーマシューティカルズ, インコーポレイテッド 複素環式プロテインキナーゼ阻害剤
EP2634190A1 (en) 2012-03-01 2013-09-04 Lead Discovery Center GmbH Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhinitors
EP2634189A1 (en) 2012-03-01 2013-09-04 Lead Discovery Center GmbH Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhibitors
GB201403093D0 (en) 2014-02-21 2014-04-09 Cancer Rec Tech Ltd Therapeutic compounds and their use

Also Published As

Publication number Publication date
SMT201900266T1 (it) 2019-07-11
US9932344B2 (en) 2018-04-03
ME03427B (me) 2020-01-20
AU2015220560A1 (en) 2016-10-06
US10927119B2 (en) 2021-02-23
PL3107914T3 (pl) 2019-09-30
BR112016018633B1 (pt) 2022-08-30
BR112016018633A2 (OSRAM) 2017-08-08
LT3107914T (lt) 2019-05-27
TR201905647T4 (tr) 2019-05-21
JP2017506250A (ja) 2017-03-02
US20180273540A1 (en) 2018-09-27
HUE043122T2 (hu) 2019-08-28
HRP20190685T1 (hr) 2019-06-14
US20160362410A1 (en) 2016-12-15
EP3107914B1 (en) 2019-01-30
JP6498212B2 (ja) 2019-04-10
RS58704B1 (sr) 2019-06-28
NZ724323A (en) 2022-02-25
CN106103445B (zh) 2019-08-09
GB201403093D0 (en) 2014-04-09
EP3107914A1 (en) 2016-12-28
ES2721268T3 (es) 2019-07-30
CY1121588T1 (el) 2020-05-29
US20210253583A1 (en) 2021-08-19
US20200055862A1 (en) 2020-02-20
CA2939786C (en) 2022-03-08
CA2939786A1 (en) 2015-08-27
EP3107914B8 (en) 2019-07-17
WO2015124941A1 (en) 2015-08-27
US11566029B2 (en) 2023-01-31
US10414772B2 (en) 2019-09-17
DK3107914T3 (en) 2019-04-29
CN106103445A (zh) 2016-11-09
SI3107914T1 (sl) 2019-05-31
AU2015220560B2 (en) 2019-05-16

Similar Documents

Publication Publication Date Title
SMT201900266T1 (it) Composti di pirazolo[1,5-a]piramidin-5,7-diammina come inibitori di cdk e loro uso terapeutico
IL260923B (en) History of pyrazolo[5,1-a]pyrazin-4-yl as jak inhibitors
IL254224A0 (en) 7-substituted 5-alkyl-[4,2,1]triazolo[5,1-a]pyrimidine derivatives as pde2 inhibitors
HK1245247A1 (zh) 溴结构域的抑制剂
IL266305B (en) History of [4,2,1]triazolo[5,1-a]pyrimidine as pde2 inhibitors
ZA201802842B (en) [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compound
IL247947B (en) 7,6,5,4-tetrahydro-pyrazolo[5,1-a]pyrazine compounds and 8,7,6,5-tetrahydro-h4-pyrazolo[5,1-a][4,1]diazepine compounds as ros1 inhibitors
ZA201800485B (en) Pyrazolo[1,5-a]triazin-4-amine derivatives useful in therapy
ZA201605666B (en) Pyrazolo[1,5-a]pyrimidines as antiviral compounds
IL290419A (en) Imidazo[a-1,5]pyrazine derivatives as inhibitors of pi3k delta
ZA201701207B (en) [1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases
IL258070A (en) Cyclic ether history of pyrazolo[5,1-a]pyrimidine-3-carboxamide
IL253427B (en) The result of pyrazolo[3,4-d]pyrimidine and its use in the treatment of Jericho rose